Alzheimer's disease and immune activation: A translational perspective
Article first published online: 24 MAR 2005
Copyright © 2004 Wiley-Liss, Inc.
Neuroscience Research Communications
Volume 35, Issue 3, pages 193–201, November/December 2004
How to Cite
Bossù, P., Ciaramella, A., Moro, M. L., Spalletta, G. and Caltagirone, C. (2004), Alzheimer's disease and immune activation: A translational perspective. Neurosci. Res. Comm., 35: 193–201. doi: 10.1002/nrc.20033
- Issue published online: 24 MAR 2005
- Article first published online: 24 MAR 2005
- Manuscript Accepted: 26 NOV 2004
- Cited By
- Alzheimer's disease;
Alzheimer's Disease (AD) is a neurodegenerative disorder characterised by abnormal fibrillar deposits of amyloid beta peptides (Aβ), which are suggested to play a pivotal role in driving disease pathogenesis. Although the aetiology of AD is still unknown, a perturbation of the immune system has been widely demonstrated in both animal experimental models and patients. The most studied aspect of immune reaction in AD is inflammation, which has been described to be implied in its pathogenic processes. Moreover, a growing body of evidence, indicating that the triggering of the specific Aβ immune response can be effective in reducing AD sympotoms, suggest that a dysregulated network of innate and adaptive immune mechanismsm could be critical in AD pathogenic process. The present short review, aimed to summarise some of the principal research studies on immune activation in AD, has the intent to provide suggestions useful to formulate new immune-therapeutic strategies for pathology treatment.